CASE REPORT article
Front. Allergy
Sec. Therapies and Therapeutic Targets
Volume 6 - 2025 | doi: 10.3389/falgy.2025.1698053
Case Report: Dupilumab Combined with Allergen-Specific Immunotherapy in Severe Atopic Dermatitis and Asthma
Provisionally accepted
- MEDICAL CENTRE HOSPITAL OF PRESIDENT’S AFFAIRS ADMINISTRATION OF THE REPUBLIC OF KAZAKHSTAN, Nur-sultan, Kazakhstan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
We report a case of a 24-year-old man with long-standing, severe atopic dermatitis and partly controlled moderate bronchial asthma, marked type-2 inflammation and high molecular sensitization to house-dust mite and Alternaria allergens. Because the patient’s disease was refractory to conventional topical and systemic therapies, we initiated dupilumab (600 mg SC loading dose, then 300 mg every 2 weeks) to rapidly suppress systemic T2 inflammation; subcutaneous allergen-specific immunotherapy (house-dust-mite and Alternaria, Clustek®) was started at week 8. Clinical scores and lung function were followed longitudinally, and serial biomarkers (total IgE, peripheral eosinophils, allergen-specific IgG4) were measured.
Keywords: atopic dermatitis, bronchial asthma, Dupilumab, allergen-specific immunotherapy, type 2 inflammation
Received: 03 Sep 2025; Accepted: 06 Oct 2025.
Copyright: © 2025 Tussupbekova, Tashenov, Syzdykova and Davletova. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Galiya Tussupbekova, tussupbekova_1108@mail.ru
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.